ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: () Report Updated: Nov 24, 2014 | Print This Page

Get more stock ratings by Louis Navellier

(GENT)

Rating: Volatility:
Total Grade: Industry:
Competitors:

Stock Analysis

Rating: Monthly View

A
B
C
D
F
November December January February March April May June July August September October

Rating: Weekly View

This Week: down no change
Last Week: same no change
Two Weeks Ago: up no change
service keys

© quotemedia

Company Profile

Gentium S.p.A., a biopharmaceutical company, engages in the research and development of drugs derived from DNA and DNA molecules. It focuses on the development and manufacture of its primary product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded DNA extracted from pig intestines. The company develops defibrotide for the treatment and prevention of hepatic veno-occlusive disease (VOD), a condition in which veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation treatments that are administered prior to stem cell transplantation. It has completed a Phase III clinical trial of defibrotide for the treatment of severe VOD in the United States, Canada, and Israel; and a Phase II/III pediatric trial in Europe for the prevention of VOD. It also develops and sells sulglicotide, an active pharmaceutical ingredient (API) developed from swine duodenum for ulcer healing and gastrointestinal protection; and urokinase, an API made from human urine to dissolve fibrin clots. The company was formerly known as Pharma Research S.r.L. and changed its name to Gentium S.p.A. in July 2001. Gentium S.p.A. was founded in 1993 and is headquartered in Villa Guardia, Italy.

Recent News: